Cinven buys Mercury Pharma from HgCapital for $732 mln
LONDON Aug 17 (Reuters) - Investor HgCapital has sold British pharmaceutical company Mercury Pharma to private equity firm Cinven for 465 million pounds ($732 million).
"The realisation of Mercury Pharma marks the continued development of HgCapital's investment focus in the healthcare sector," said HgCapital's head of healthcare, Philipp Schwalber, in a statement on Friday.
"We continue to seek out businesses that enjoy niches of secular growth despite the challenges facing much of the healthcare space," he said.
HgCapital bought the 25-year-old pharmaceutical firm, which sells niche prescription off-patent products in the UK, Ireland and the Netherlands, in 2009.
It said its listed investment trust HgCapital Trust expects to receive 35.4 million pounds in cash on the sale completion and further potential proceeds of 1 million pounds over the next 30 months.
- Tweet this
- Share this
- Digg this
- Alabama man claims penis was amputated by mistake
- Russian military likely reluctant participants in Ukraine-US general
- UPDATE 4-Liberian man in Lagos being tested for Ebola
- 'Weird Al' Yankovic still trying to wrap head around No. 1 album
- UPDATE 2-U.S. says Russia firing artillery over border at Ukraine military
India blocked an agreement on new global customs rules on Thursday, angering fellow members of the World Trade Organization who say Delhi's veto could be costly, economically and politically. Full Article